Pharmalot... Pharmalittle... Good Morning

Rise and shine. Another busy day is on the way. And by all indications, this is going to be a hot one, at least in the region in which the Pharmalot corporate campus is situated. Who says summer is over? To keep cool, we plan to brew an iced glass or two of delicious stimulation. This requires foraging for the proper equipment. So while we do so, here are some items of interest to start the day. Hope you accomplish everything on your agenda and, as always, reach out if you run across anything intriguing... AstraZeneca Pays $50M To Merck For Cancer Drug (Reuters) Merck R&D Chief Tells Analysts Further R&D Changes Are Planned (Bloomberg News) FDA Panel Backs Glaxo And Theravance COPD Drug (MedPage Today) IOM Says Cancer Care Delivery Is In Crisis (Reuters) Biogen And Amicus Sign Deal For Parksinson's Research (Pharma Times) Boehringer Encounters Conflicting Data On Spiriva Safety (MedPage Today) United Health Recalls Rx Records Software Due To Glich (Reuters) India Wants Drugmakers To Focus On Tropical Diseases (PharmaBiz) EDITOR'S NOTE: Please check this post for additional stories during the day Read more
Source: Pharmalot - Category: Pharma Commentators Authors: Source Type: blogs